MnSOD Val16 Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Published data on the association between manganese superoxide dismutase (MnSOD) Val16Ala polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimate of the association between them, a meta-analysis was performed.
PubMed and Embase were searched. All eligible studies were retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) for PCA risk associated with Val/Ala versus Val/Val, Ala/Ala versus Val/Val, dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val) were estimated, respectively.
A total of 12 studies including 8,962 subjects were involved in this meta-analysis. Overall, the meta-analysis indicated that significantly elevated cancer risk was associated with Ala variant genotype when all the eligible studies were pooled into the meta-analysis (for Val/Ala vs. Val/Val: OR = 1.11, 95% CI = 1.00–1.24; for Ala/Ala vs. Val/Val: OR = 1.22, 95% CI = 1.00–1.49; for dominant model: OR = 1.14, 95% CI = 1.03–1.26). In the subgroup analysis by ethnicity, statistically significant increased risks were found among Caucasians with Ala allele (for Val/Ala vs. Val/Val: OR = 1.12, 95% CI = 1.00–1.25; for dominant model: OR = 1.14, 95% CI = 1.02–1.26). However, no significant associations were found in Africans.
This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.
- MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects
Journal of Cancer Research and Clinical Oncology
Volume 136, Issue 7 , pp 975-979
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Prostate cancer
- Industry Sectors
- Author Affiliations
- 1. Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China
- 2. Department of Medical Oncology, Cancer Hospital, Fudan University, 270 Dong An Road, 200032, Shanghai, People’s Republic of China
- 3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- 4. Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, China
- 5. Longgang Center for Disease Control and Prevention of Shenzhen, Shenzhen, China
- 6. Department of Respiratory Medicine, Hefei Second People’s Hospital, Hefei, China